(Q36949302)

English

Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody

scientific article published on August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

17 August 2017

Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody (English)

1 reference

Europe PubMed Central

17 August 2017

author name string

Marta Bellone

1

1 reference

Europe PubMed Central

17 August 2017

Emiliano Cocco

2

1 reference

Europe PubMed Central

17 August 2017

Joyce Varughese

3

1 reference

Europe PubMed Central

17 August 2017

Stefania Bellone

4

1 reference

Europe PubMed Central

17 August 2017

Paola Todeschini

5

1 reference

Europe PubMed Central

17 August 2017

Karim El-Sahwi

6

1 reference

Europe PubMed Central

17 August 2017

Luisa Carrara

7

1 reference

Europe PubMed Central

17 August 2017

Federica Guzzo

8

1 reference

Europe PubMed Central

17 August 2017

Peter E Schwartz

9

1 reference

Europe PubMed Central

17 August 2017

Thomas J Rutherford

10

1 reference

Europe PubMed Central

17 August 2017

Sergio Pecorelli

11

1 reference

Europe PubMed Central

17 August 2017

Deborah J Marshall

12

1 reference

Europe PubMed Central

17 August 2017

Alessandro D Santin

13

1 reference

Europe PubMed Central

17 August 2017

publication date

1 August 2011

1 reference

Europe PubMed Central

17 August 2017

International Journal of Gynecological Cancer

1 reference

Europe PubMed Central

17 August 2017

21

1 reference

Europe PubMed Central

17 August 2017

6

1 reference

Europe PubMed Central

17 August 2017

1084-1090

1 reference

Europe PubMed Central

17 August 2017

Integrins as therapeutic targets: lessons and opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Cancer statistics, 2010

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Important role of integrins in the cancer biology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Precursors of endometrial and ovarian carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Insights into endometrial serous carcinogenesis and progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

CNTO 95, a fully human anti alphav integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Alpha-v integrins as therapeutic targets in oncology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Integrins: molecular targets in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Integrins: bidirectional, allosteric signaling machines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

29 September 2017

Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3690508

4 September 2018

Overexpression of the alphavbeta6 integrin in endometrial cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/21633302

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Absence of adverse effects in cynomolgus macaques treated with CNTO 95, a fully human anti-alphav integrin monoclonal antibody, despite widespread tissue binding

1 reference

https://pubmed.ncbi.nlm.nih.gov/21633302

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cance

1 reference

https://pubmed.ncbi.nlm.nih.gov/21633302

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/IGC.0B013E3182187324

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

1 reference

Europe PubMed Central

17 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36949302&oldid=1514743870"